Altrinsic Global Advisors’s Jazz Pharmaceuticals JAZZ Stock Holding History

Altrinsic Global Advisors’s Portfolio JAZZ Stock Details JAZZ Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2022 Q1	–	Sell	-21,000	Closed	-$2.67M	–	62
2021 Q4	$2.67M	Hold	21,000	–	–	0.09%	54
2021 Q3	$2.73M	Buy	21,000 +6,000	+40%	+$907K	0.08%	58
2021 Q2	$2.67M	Hold	15,000	–	–	0.08%	58
2021 Q1	$2.47M	Hold	15,000	–	–	0.08%	61
2020 Q4	$2.48M	Hold	15,000	–	–	0.08%	56
2020 Q3	$2.14M	Buy	+15,000	New	+$1.86M	0.09%	54

Other funds holding JAZZ

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return

State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return

LSV Asset Management Chicago, Illinois $55.1B AUM 45.38% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return

PCM

Polaris Capital Management Boston, Massachusetts $1.06B AUM 40.82% 1-Year Est. Return

Canada Pension Plan Investment Board Toronto Ontario, Ontario, Canada $181B AUM 41.77% 1-Year Est. Return

Altrinsic Global Advisors's JAZZ Position: Q1 2022 in Review

Altrinsic Global Advisors sold out of Jazz Pharmaceuticals (JAZZ) in Q1 2022, closing a stake of 21,000 shares — an estimated $2.67M sold.

Altrinsic Global Advisors first reported a position in JAZZ in Q3 2020 and held it in 6 quarters. The position peaked at $2.73M in Q3 2021. 462 funds tracked by Wall St. Rank hold JAZZ as of Q1 2022.

Altrinsic Global Advisors reported no remaining Jazz Pharmaceuticals position as of Q1 2022 after selling out during the quarter.
Altrinsic Global Advisors sold 21,000 Jazz Pharmaceuticals shares in Q1 2022, an estimated $2.67M.
Altrinsic Global Advisors first reported a position in Jazz Pharmaceuticals in Q3 2020 and held it in 6 quarters.
Altrinsic Global Advisors's Jazz Pharmaceuticals position peaked at $2.73M in Q3 2021.
462 funds tracked by Wall St. Rank held Jazz Pharmaceuticals as of Q1 2022.

Based on Altrinsic Global Advisors's 13F filing for Q1 2022, filed 16 May 2022.